



February 12, 2021.

To  
The General Manager  
Dept. of Corporate Services – CRD  
The Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.

**Sub: Outcome of the Board Meeting Dt. 12-02-2021**

**Ref: Regulation 30 & 33 of the SEBI (LODR) Regulations, 2015.**

**Unit: Godavari Drugs Limited – Script Code (530317).**

Dear Sir,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors of the Company at its meeting held today at 11.00 a.m through Video Conferencing and concluded at 12:20 p.m inter alia transacted the following business:

1. Un audited financial results for the quarter and nine months ended ended 31<sup>st</sup> December, 2020 were considered, reviewed and adopted by the Board of Directors of the Company along with the Limited Review Report.
2. The Board of Directors discussed and taken note of the Compliance Report placed before the Board, with regard to compliances under the various applicable laws, Acts and Regulation.
3. Extract of the result as given for publication in the newspaper Andhra prabha and Business standard.

The meeting concluded at 12:20 p.m.

For Godavari Drugs Limited

Narendra Maddineni



**Company Secretary & Compliance Officer**



**GODAVARI DRUGS LIMITED**  
CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECMEBER 31, 2020

(Rs. In Lakhs)


Sl. No.	Particulars	Quarter ended			Nine months ended on		Year ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	3309.92	3092.03	2591.12	8971.17	7126.04	9569.77
2	Other Income	8.18	20.50	1.68	29.61	9.58	32.77
3	<b>Total Revenue from operations (1+2)</b>	<b>3318.10</b>	<b>3112.53</b>	<b>2592.80</b>	<b>9000.78</b>	<b>7135.62</b>	<b>9602.54</b>
4	<b>Expenses</b>						
	(a) Cost of materials consumed	2111.80	2488.37	1948.62	6985.57	5732.58	7738.19
	(b) Changes in inventories of finished goods & work-in-progress	550.48	-13.28	131.51	141.47	-64.58	-71.11
	(c) Employee benefits expense	107.81	89.57	85.82	275.16	249.68	344.51
	(d) Depreciation & amortization expense	28.80	28.13	29.94	84.78	88.62	116.26
	(e) Finance Costs	81.70	83.17	70.86	249.75	206.66	291.15
	(f) Other Expenses	282.94	284.95	247.96	842.95	736.97	954.65
	<b>Total expenses</b>	<b>3163.53</b>	<b>2960.91</b>	<b>2514.71</b>	<b>8579.68</b>	<b>6949.93</b>	<b>9373.65</b>
5	<b>Profit before exceptional Items and tax (3-4)</b>	<b>154.57</b>	<b>151.62</b>	<b>78.09</b>	<b>421.10</b>	<b>185.69</b>	<b>228.89</b>
6	Exceptional items						
7	<b>Profit before Tax (5-6)</b>	<b>154.57</b>	<b>151.62</b>	<b>78.09</b>	<b>421.10</b>	<b>185.69</b>	<b>228.89</b>
8	<b>Tax expense</b>	<b>-54.31</b>	<b>-52.78</b>	<b>-24.03</b>	<b>-136.93</b>	<b>-61.15</b>	<b>-28.82</b>
	<b>Total Tax Expenses</b>						
9	<b>Net Profit for the period (7-8)</b>	<b>100.26</b>	<b>98.84</b>	<b>54.06</b>	<b>284.17</b>	<b>124.54</b>	<b>200.07</b>
10	<b>Other Comprehensive Income</b>						
	(i) Items that will not be reclassified to profit or loss					-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss					-	-
	(iii) Items that will be reclassified to profit or loss					-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss					-	-
	<b>Total Other Comprehensive Income (Net of Tax)</b>					-	-
11	<b>Total Comprehensive Income (9+10)</b>	<b>100.26</b>	<b>98.84</b>	<b>54.06</b>	<b>284.17</b>	<b>124.54</b>	<b>200.07</b>
12	Paid-up equity share capital	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity						1272.76
14	<b>Earnings per share</b>						
	(a) Basic	1.33	1.31	0.72	3.77	1.65	2.66
	(b) Diluted	1.33	1.31	0.72	3.77	1.65	2.66

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 12th February, 2021
- The above results were prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Limited Review by the Statutory Auditors for the quarter as required under regulation 33(3)(c) the Listing Agreement has been received.
- The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30<sup>th</sup> November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5<sup>th</sup> July, 2016, Ind AS Schedule III ( Division II ) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- As per Regulation 33 of SEBI ( Listing Obligations and Disclosure Requirements ) Regulations, 2015, the company has opted to publish quarterly unaudited results at the quarter end.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.

Place: Secunderabad  
Date: 12-02-2021

For GODAVARI DRUGS LIMITED

*K. K. Jain*  
K.K.Jain  
Director Finance  
DIN: 00076657





**Independent Auditor's Review Report on unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**


To,  
The Board of Directors  
Godavari Drugs Limited.

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and nine months ended 31<sup>st</sup> December, 2020 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V Sridhar & Co  
Chartered Accountants  
FRN: 006206S



Vemulapati Sridhar  
Proprietor  
Membership No.202337.  
Hyderabad. February 12, 2021.  
UDIN: 21202337AAAABT8858.





**GODAVARI DRUGS LIMITED**  
CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2020

(Rs. In Lakhs)

Particulars	Quarter ended 31.12.2020 (Unaudited)	Quarter ended 30.09.2020 (Unaudited)	Quarter ended 31.12.2019 (Unaudited)	Nine months period ended on 31.12.2020 (Unaudited)	Nine months period ended on 31.12.2019 (Unaudited)	Year ended 31.03.2020 (Audited)
Total Revenue from operations (Net)	3318.10	3112.53	2592.80	9000.78	7135.62	9602.54
Net profit/ (Loss) for the period (before Tax, Exceptional and / or Extra Ordinary Items)	154.57	151.62	78.09	421.10	185.69	228.89
Net profit/ (Loss) for the period (before Tax after Exceptional and / or Extra Ordinary Items)	154.57	151.62	78.09	421.10	185.69	228.89
Net profit/ (Loss) for the period (after tax after Exceptional and / or Extra Ordinary Items)	100.26	98.84	54.06	284.17	124.54	200.07
Total Comprehensive Income for the period						
[Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	100.26	98.84	54.06	284.17	124.54	200.07
Equity Share Capital	753.05	753.05	753.05	753.05	753.05	753.05
Reserves						1272.76
Earnings per share for continuing and discontinues operations						
Basic	1.33	1.31	0.72	3.77	1.65	2.66
Diluted	1.33	1.31	0.72	3.77	1.65	2.66

**Notes:**

- The above is an extract of the detailed format of financial results for the nine months period ended December 31, 2020 filed with the Stock Exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time.
- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th February, 2021

For GODAVARI DRUGS LIMITED

*K.K. Jain*  
K.K. Jain

Director Finance  
DIN: 00076657



Place: Secunderabad

Date: February 12, 2021